Search clinical trials for: interferons

Total 1114 results

Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia (STEADFAST)

Friedreich's Ataxia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Chicago

Unknown

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Immune System Diseases | Multiple Sclerosis

United States
Bayer

Completed

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Multiple Sclerosis, Relapsing Remitting

Belgium, Bosnia and Herzegovina, Italy, Austria, Croatia, Czechia, France, Greece, Hungary, Spain, Switzerland
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Bayer

Completed

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Multiple Sclerosis

Germany
Hoffmann-La Roche

Completed

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Hepatitis C, Chronic

Canada
Hoffmann-La Roche

Completed

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Hepatitis C, Chronic

Georgia
Radboud University Medical Center

Completed

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

Sepsis | Septic Shock

Netherlands
Replicor Inc.

Completed

REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

Chronic HBV Infection (HBeAg Negative)

Moldova, Republic of
Pawel Kalinski

Withdrawn

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Novartis

Completed

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase (TRANSFORMS)

Multiple Sclerosis

United States, Korea, Republic of, Portugal, Canada, Hungary, Spain, Germany, United Kingdom, Australia, Argentina, Austria, Belgium, Brazil, Egypt, France, Greece, Italy, Switzerland
National Institute of Allergy and Infectious Diseases...

Terminated

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

IFN-Gamma Therapy | CGD Gene Mutation | CGD Response to IFNg | CGD - Chronic Granulomatous Disease | Immunodeficiency Disease

United States
Beth Israel Deaconess Medical Center
Biogen

Completed

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis (CHAMPIONS10)

Multiple Sclerosis | Optic Neuritis | Transverse Myelitis | Acute Brainstem/Cerebellar Syndrome

United States, Canada
Lisa H. Butterfield, Ph.D.
National Cancer Institute (NCI)

Completed

Multiple Antigen-Engineered DC Vaccine for Melanoma

Melanoma

United States
HepNet Study House, German Liverfoundation
Hannover Medical School

Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)

Hepatitis C, Chronic

Germany
Coordinación de Investigación en Salud, Mexico
University of Guadalajara; Instituto Mexicano del Seguro Social

Completed

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Conjunctival Intraepithelial Neoplasia | Corneal Intraepithelial Neoplasia

Mexico
Bristol-Myers Squibb

Completed

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Psoriasis

Australia
Seoul National University Hospital

Unknown

Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT

Latent Tuberculosis | Tuberculosis, Pulmonary

Korea, Republic of
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Beth Israel Deaconess Medical Center
Schering-Plough

Completed

Study of Long-term Peg Intron vs. Colchicine in Non-responders. (COPILOT)

Cirrhosis | Hepatitis C Virus | Advanced Fibrosis

United States
National Institute of Diabetes and Digestive and...

Completed

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

Zollinger Ellison Syndrome | Islet Cell Adenoma

United States
National Institute of Neurological Disorders and...

Completed

Safety Study of Interferon Beta 1a to for Acute Stroke

Cerebrovascular Accident

United States
National Eye Institute (NEI)

Completed

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

Uveitis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

Mycobacterium Avium-Intracellulare Infection

United States
Baylor Research Institute

Withdrawn

Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.

Lymphoma
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States
GlaxoSmithKline
PPD

Completed

Dose Ranging of GSK2336805 in Combination Therapy (HAI115879)

Hepatitis C, Chronic

Puerto Rico, United States, Bulgaria, Germany, Belgium, France
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Melanoma

United States
University College, London

Active, not recruiting

Testing for Tuberculosis in the United Kingdom HIV Infected Population

HIV | Latent Tuberculosis

United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

Melanoma (Skin)
Tianjin SinoBiotech Ltd.

Completed

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

Healthy

China
University Hospital Tuebingen
Dermatologic Cooperative Oncology Group

Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Melanoma

Germany
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Sheikh Zayed Medical College

Completed

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Hepatitis C | Hepatitis C Relapse

Pakistan
Azienda Policlinico Umberto I

Completed

A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients

Friedreich Ataxia

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Recurrent Merkel Cell Carcinoma | Stage IV Merkel Cell Carcinoma

United States
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)

Multiple Sclerosis, Relapsing-Remitting

Australia, Denmark, Canada, United States, Netherlands, Argentina, Austria, Belgium, Brazil, Croatia, Czech Republic, France, Germany, Israel, Italy, Mexico, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine, United Kingdom
University of Southern California

Terminated

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Thrombocytopenia | Hepatitis C Infection

United States
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic

3

Subscribe